{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-25-000018","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.006415+00:00","generated_at":"2026-05-22T17:30:44.718863+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inspire Medical Q1 rev $201.3M (+23% YoY), EPS $0.10; raises FY EPS guidance to $2.20-$2.30","bullets":["Revenue $201.3M, up 23% YoY; U.S. revenue $193.6M (+24%), OUS $7.7M (-6%).","Net income $3.0M (diluted EPS $0.10) vs net loss $10.0M ($0.34 loss) in Q1 2024.","Adjusted EBITDA $33.2M, up from $11.9M; operating loss improved 90% to $1.5M.","Surpassed 100,000 patients on Inspire therapy; Inspire V system launch starting in U.S. May 2025.","FY 2025 revenue guidance maintained $940-955M; EPS guidance raised to $2.20-$2.30 (from $2.10-$2.20)."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-25-000018","json":"https://secwatch.observer/filing/0001609550-25-000018.json","markdown":"https://secwatch.observer/filing/0001609550-25-000018.md","text":"https://secwatch.observer/filing/0001609550-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955025000018/0001609550-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955025000018/insp-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T17:30:44.718863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}